This Pharmaceutical training examines the system its benefits and its drawbacks and how effective is the system established between the EMEA and the FDA. The authorization of medical products by the FDA is not recognized in the EU. Neither is authorization by the EMEA Recognized by the FDA.
In an attempt to resolve this lack of mutual Recognition, the EU and the US have established a system of parallel scientific advice. This Webinar examines the system its benefits and its drawbacks.
In an attempt to resolve this lack of mutual Recognition, the EU and the US have established a system of parallel scientific advice. This Webinar examines the system its benefits and its drawbacks.
Areas Covered in the seminar:
- The background to establishment of the system of parallel scientific Advice
- The practical application of the system
- Examples of the system in practice
Who Will Benefit:
- pharmaceutical companies
- Pharmaceutical innovative companies, whose market covers both the US and the member states of the EU
- Scientists
- Buyers
- Regulatory affairs specialist
Course Provider
Elisabethann Wright,
